Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103635 · ClinicalTrials.gov registry record · Phase 1
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
A Phase 1 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01103635 is a Phase 1 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 25 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01103635, a Phase 1 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL tremelimumab
- BIOLOGICAL CD40 agonist monoclonal antibody CP-870,893
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-02 |
| Est. Completion | 2016-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103635
The ClinicalTrials.gov registry entry for NCT01103635 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (85% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01103635 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01103635 about?
NCT01103635 is a clinical study titled "Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma". RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tr...
What is the current status of trial NCT01103635?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-02. Estimated completion is 2016-05-02.
What conditions does trial NCT01103635 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma.
What interventions are being tested in trial NCT01103635?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tremelimumab (BIOLOGICAL), CD40 agonist monoclonal antibody CP-870,893 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01103635?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01103635 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
RECRUITING · Phase 1
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.